Scorpius Holdings Inc - Company Profile
Powered by 
All the data and insights you need on Scorpius Holdings Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Scorpius Holdings Inc Strategy Report
- Understand Scorpius Holdings Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Scorpius Holdings Inc (Scorpius Holdings), formerly NightHawk Biosciences Inc, is a leading biotechnology company specializing in the development and commercialization of advanced medical technologies and therapies. Its major commercially available product is Anthim (obiltoxaximab), an FDA-approved monoclonal antibody specifically developed for the treatment of inhalational anthrax. Anthim has received orphan drug exclusivity, highlighting its unique status in addressing this serious medical condition. It is also approved in Europe, Canada and the UK. Scorpius Holdings is headquartered in Morrisville, North Carolina, the US.
Headquarters
United States of America
Address
627 Davis Drive, Suite 400, Morrisville, North Carolina, 27560
Website
www.nighthawkbio.com
Telephone
1 919 2407133
No of Employees
77
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SCPX (AFM)
Revenue (2022)
$6.4M
EPS
XYZ
Market Cap*
$5.7M
Net Profit Margin (2022)
XYZ
59.0%
* As of and is in US$
Scorpius Holdings Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Anthim (obiltoxaximab) | CDMO services |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In February, the company changed its name from NightHawk Biosciences Inc to Scorpius Holdings Inc and trade under new symbol SCPX. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with the university to create and commercialize a new biologic that targets substance use disorders such as drug, alcohol, and opioid addiction. |
| 2022 | Corporate Changes/Expansions | In August, the company announced the construction of an advanced biosafety level 2 (BSL-2) laboratory in the research facilities in Research Triangle Park, North Carolina. |
Competitor Comparison
| Key Parameters | Scorpius Holdings Inc | Lonza Group Ltd | WuXi AppTec Co Ltd | Emergent BioSolutions Inc | Precigen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | China | United States of America | United States of America |
| City | Morrisville | Basel | Shanghai | Gaithersburg | Germantown |
| State/Province | North Carolina | - | Shanghai | Maryland | Maryland |
| No. of Employees | 77 | 17,896 | 44,361 | 2,500 | 209 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey Wolf | Chief Executive Officer; Chairman; President | Executive Board | 2008 | 59 |
| William Ostrander | Chief Financial Officer; Secretary | Senior Management | 2021 | 55 |
| Anthony Manning | Chief Scientific Advisor | Senior Management | 2021 | - |
| Paul Tebbey, Ph.D. | Senior Vice President - Product Development and Portfolio Strategy | Senior Management | - | - |
| Guillermo (Bill) Arana | Vice President - Clinical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward